Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
78.4M
-
Number of holders
-
131
-
Total 13F shares, excl. options
-
48.2M
-
Shares change
-
+6.78M
-
Total reported value, excl. options
-
$1.31B
-
Value change
-
+$189M
-
Put/Call ratio
-
0.01
-
Number of buys
-
94
-
Number of sells
-
-26
-
Price
-
$27.20
Significant Holders of Replimune Group, Inc. - COMMON STOCK (REPL) as of Q4 2022
141 filings reported holding REPL - Replimune Group, Inc. - COMMON STOCK as of Q4 2022.
Replimune Group, Inc. - COMMON STOCK (REPL) has 131 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 48.2M shares
of 78.4M outstanding shares and own 61.46% of the company stock.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (5.06M shares), Redmile Group, LLC (4.83M shares), BAKER BROS. ADVISORS LP (4.58M shares), Omega Fund Management, LLC (3.36M shares), BlackRock Inc. (3.01M shares), VANGUARD GROUP INC (2.24M shares), Atlas Venture Life Science Advisors, LLC (2.1M shares), BVF INC/IL (1.52M shares), STATE STREET CORP (1.48M shares), and FMR LLC (1.38M shares).
This table shows the top 131 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.